TriSalus Life Sciences (TLSI)

• Market cap: $166M
• 1 day: -10.31%
• 5 days: -10.47%
• 1 month: -7.07%
• 3 months: 0.39%
• 6 months: 28.89%
• Year to date: 3.01%
• 1 year: -44.90%
• 5 years: -51.24%
• 10 years: -51.24%
• Sector: Healthcare
• Industry: Medical Devices

About: TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Employees: 110

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

23% more capital invested

Capital invested by funds: $10M [Q3] → $12.4M (+$2.35M) [Q4]

0.68% more ownership

Funds ownership: 7.41% [Q3] → 8.09% (+0.68%) [Q4]

9% less funds holding

Funds holding: 32 [Q3] → 29 (-3) [Q4]

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 95% upside
• Avg. target: $10.50 105% upside
• High target: $11 114% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity William Plovanic 44% 1-year accuracy 21 / 48 met price target	114% upside $11	Buy Maintained	28 Mar 2025
Lake Street	95% upside $10	Buy Initiated	13 Feb 2025